Baird analyst Brian Skorney reiterated an Outperform rating and bumped his price target on Neurocrine Bio. (NASDAQ: NBIX) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Leerink Partners Raises Price target on Neurocrine Biosciences (NBIX) Following Positive KINECT3 Results October 8, 2015 2:49 PM Neurocrine Bio. (NBIX) Bullish Stance Reiterated at CowenOctober 8, 2015 12:46 PM Neurocrine Bio (NBIX) PT Raised to $96 at Piper JaffrayOctober 8, 2015 10:52 AM Neurocrine Biosciences (NBIX) Announces Significant Data from NBI-98854 Kinect 3 in Lardive DyskinesiaOctober 8, 2015 6:34 AM